A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

October 14, 2025

Primary Completion Date

May 31, 2029

Study Completion Date

May 31, 2029

Conditions
Small-cell Lung Cancer
Interventions
DRUG

IDE849

IV administration

Trial Locations (10)

10032

NOT_YET_RECRUITING

Columbia University Medical Center - Herbert Irving Pavilion, New York

19107

NOT_YET_RECRUITING

Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia

22031

RECRUITING

NEXT Oncology Virginia, Fairfax

37203

NOT_YET_RECRUITING

Sarah Cannon Research Institute - Oncology Partners, Nashville

49546

RECRUITING

The Cancer and Hematology Centers, Grand Rapids

60637

NOT_YET_RECRUITING

The University of Chicago Medical Center - Duchossois Center for Advanced Medicine, Chicago

75039

RECRUITING

Next Oncology Dallas, Irving

77030

NOT_YET_RECRUITING

MD Anderson, Houston

80218

NOT_YET_RECRUITING

Sarah Cannon Research Institute at HealthONE, Denver

98104

NOT_YET_RECRUITING

Swedish Cancer Institute, Seattle

Sponsors

Lead Sponsor

All Listed Sponsors
lead

IDEAYA Biosciences

INDUSTRY